Oct. 10 (Bloomberg) -- Roche Holding AG and Morphosys AG’s experimental Alzheimer’s treatment gantenerumab appeared to reduce the build-up in the brain of beta amyloid plaque thought to be linked to the disease, according to a study published today in Archives of Neurology.
Roche, based in Basel, Switzerland, sponsored the 16-person study, which wasn’t intended to prove whether gantenerumab helps patients. The drug is already being tested in a bigger mid-stage study to help determine its effectiveness for people with early symptoms of Alzheimer’s disease.
To contact the reporter on this story: Naomi Kresge in Berlin at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com